Outlook Therapeutics® Streamlines Operations
ISELIN, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this